Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL versus XYLOCAINE DENTAL WITH EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL versus XYLOCAINE DENTAL WITH EPINEPHRINE.
Labetalol vs XYLOCAINE DENTAL WITH EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Lidocaine blocks voltage-gated sodium channels (Nav1.5, Nav1.7, Nav1.8) in nerve cell membranes, inhibiting sodium influx and preventing depolarization and conduction of nerve impulses. Epinephrine acts as a local vasoconstrictor via alpha-1 adrenergic receptor agonism, reducing systemic absorption and prolonging anesthetic effect.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
Dose range: 1.0–5.0 mL of 2% lidocaine with 1:100,000 epinephrine (20–100 mg lidocaine) injected locally. Maximum dose: 7 mg/kg lidocaine, not to exceed 500 mg total. Epinephrine component limits: 0.2 mg per visit (200 mcg). Repeat doses after 2–3 hours based on response.
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
None Documented
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Terminal elimination half-life of lidocaine is approximately 1.5–2 hours in adults, but can be prolonged to 3–5 hours in patients with hepatic impairment or congestive heart failure.
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Lidocaine is primarily metabolized in the liver; less than 10% is excreted unchanged in urine. Metabolites are excreted renally. Biliary/fecal excretion is minimal.
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist